Overview

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Status:
Terminated

Trial end date:
2019-12-30

Target enrollment:

Participant gender:

Summary

A dose escalation trial to assess the safety of plerixafor in patients with advanced pancreatic, high grade serous ovarian and colorectal cancer. To identify the proof of mechanism, by demonstrating alterations in T-cell tumour distribution, ideally associated with loss of tumour cells, measured by immunostaining, and changes in FDG uptake.

Phase:

Phase 1

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborator:

Cambridge University Hospitals NHS Foundation Trust

Treatments:

JM 3100
Plerixafor